Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Multiple Myeloma Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5861-D

    Medicare Part B Step Therapy Multiple Myeloma

    Customize your policy alerts

    Sign up for zing_health Policy 5861-D alerts

    Get alerted when Policy 5861-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of preferred and non-preferred multiple myeloma products for Zing Health members. Non-preferred products require prior authorization and are covered when specified clinical exception criteria are met.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Multiple Myeloma
    Policy CodePolicy 5861-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse a preferred bortezomib product first unless the member meets a documented exception for non-preferred coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Preferred bortezomib product entries
    4Non-preferred multiple myeloma products
    365 daysPrior-use lookback
    3Clinical exception pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-Preferred Product Exceptions

    Non-preferred product exceptions

    For a member requesting treatment for an indication that is FDA-approved for the preferred product, coverage for a non-preferred product is provided when ANY of the following criteria are met:

    ANY of the following

    • The member has received treatment with the non-preferred product in the past 365 days.Within the past 365 days
    • The request is for Empliciti, Kyprolis, or Sarclisa, and the member has a documented inadequate response or intolerable adverse event with a preferred product.
    • The request is for Velcade, and the member has had a documented intolerable adverse event to a preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    Covered and Non-Covered Products

    PreferredmixedCovered
    J9046bortezomib (generic)
    NDC 43598-0865-60bortezomib (generic)
    J9048bortezomib (generic)
    NDC 63323-0721-10bortezomib (generic)
    J9049bortezomib (generic)
    NDC 00409-1703-01bortezomib (generic)
    Non-preferredHCPCSNot Covered
    J9041Velcade (bortezomib)

    Authorization, Documentation, and Denial Rules

    Prior Authorization

    Prior Authorization for Non-Preferred Products

    Non-preferred products require prior authorization. The review evaluates clinical circumstances that would exclude use of the preferred product, including prior use of a product, and applies to all members requesting treatment with a non-preferred product. Applicable Medicare Part B NCD, LCD, and utilization-management requirements also apply.

    Prior Authorization

    Preferred Products May Require Review

    Preferred bortezomib products may still require a clinical prior authorization review, even though they are designated as preferred under the plan.

    • Preferred products: bortezomib (generic) J9046, J9048, and J9049.
    Step Therapy

    Use the Preferred Product First

    Use the preferred bortezomib product first for an FDA-approved indication unless a qualifying step-therapy exception applies.

    • Preferred products include bortezomib (generic) J9046, J9048, and J9049.
    • Non-preferred products include Empliciti (elotuzumab), Kyprolis (carfilzomib), Sarclisa (isatuximab), and Velcade (J9041; bortezomib).
    Documentation Required

    Document the Clinical Exception

    Document the clinical exception supporting the request for a non-preferred product. Coverage may be available when the member received the non-preferred product within the past 365 days, or when the applicable product-specific exception is documented.

    • For Empliciti, Kyprolis, or Sarclisa: document an inadequate response or intolerable adverse event with a preferred product.
    • For Velcade: document an intolerable adverse event with a preferred product and confirm it was not an expected adverse event attributable to the active ingredient as described in the prescribing information.
    Denial Risk

    Denial Risk Without a Qualifying Exception

    A non-preferred product may be denied when the request is not for an FDA-approved indication for the preferred product or when none of the qualifying exception criteria is met. Preferred-product FDA approval and the applicable exception documentation must support the request.

    • Qualifying exceptions include prior treatment with the non-preferred product within the past 365 days or the applicable documented inadequate response or intolerable adverse event.
    • For Velcade, an expected adverse event attributed to the active ingredient does not qualify as an exception.

    Policy Background

    This policy addresses Medicare Part B step therapy for multiple myeloma products. Preferred therapy consists of specified bortezomib products, while Empliciti (elotuzumab), Kyprolis (carfilzomib), Sarclisa (isatuximab), and Velcade (bortezomib) are non-preferred products. Non-preferred products are reviewed through prior authorization when clinical circumstances exclude use of the preferred product, including applicable previous product use. The program operates in addition to applicable Medicare National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization management programs.

    Initial Non-Preferred Therapy

    Initial Non-preferred Therapy

    Initial coverage of a non-preferred product requires an FDA-approved indication for the preferred product and at least one qualifying exception.

    Required indication and exception

    • At least one qualifying exception

      • Prior use: The member has received treatment with the requested non-preferred product within the past 365 days.within the past 365 days
      • Empliciti, Kyprolis, or Sarclisa exception: The request is for Empliciti, Kyprolis, or Sarclisa, and the member has a documented inadequate response or intolerable adverse event with a preferred product.
      • Velcade exception: The request is for Velcade, and the member has had a documented intolerable adverse event with a preferred product that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    Preferred Product Step Requirement

    StepRequirement
    1Use a preferred bortezomib product first for an indication that is FDA-approved for the preferred product. Coverage of the requested non-preferred product may be provided if the member received that product within the past 365 days or meets an applicable clinical exception: inadequate response or intolerable adverse event with a preferred product for Empliciti, Kyprolis, or Sarclisa; or a documented intolerable adverse event with a preferred product for Velcade that was not an expected adverse event attributed to the active ingredient.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Multiple Myeloma
    Policy CodePolicy 5861-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse a preferred bortezomib product first unless the member meets a documented exception for non-preferred coverage.
    SourceLink
    On This Page
    Non-Preferred Product ExceptionsCovered and Non-Covered ProductsAuthorization, Documentation, and Denial RulesPolicy BackgroundInitial Non-Preferred TherapyPreferred Product Step Requirement